首页|贝那普利联合阿托伐他汀对慢性心力衰竭的治疗效果及对血浆NT-proBNP水平的影响

贝那普利联合阿托伐他汀对慢性心力衰竭的治疗效果及对血浆NT-proBNP水平的影响

扫码查看
目的 探讨贝那普利联合阿托伐他汀对慢性心力衰竭的治疗效果及对血浆氨基末端脑钠肽前体(NT-proBNP)水平的影响.方法 选择2013年1月~2016年1月浙江省象山第一人民医院接诊90例慢性心力衰竭患者,通过随机数表法分为观察组和对照组,每组各45例,在常规治疗基础上,对照组使用贝那普利,观察组在对照组基础上加用阿托伐他汀.2个月后,比较治疗效果.结果 治疗后,观察组左室舒张末期内径(LVIDd)、左室收缩末期内径(LVIDs)水平比对照组低,左室射血分数(LVEF)水平高于对照组,差异有统计学意义(P<0.05);观察组氨基末端脑钠肽前体(NT-proBNP)水平低于对照组,差异有统计学意义(P<0.05);6 min步行距离优于对照组,差异有统计学意义(P<0.05);观察组总有效率91.11%(11/45)比对照组71.11%(32/45)高,差异有统计学意义(P<0.05);在6个月的随访过程中,观察组心力衰竭复发率2.22%(1/45)低于对照组20.00%(9/45),差异有统计学意义(P<0.05).结论 在慢性心力衰竭患者中给予贝那普利联合阿托伐他汀效果显著,可有效降低血浆NT-proBNP水平,改善心功能,提高预后.
Effect of benazepril combined with atorvastatin in treatment of chronic heart failure and its effects on level of plasma NT-proBNP
Objective To study curative efficacy of benazepril combined with atorvastatin in treatment of chronic heart failure and its effects on level of plasma N-terminal pro brain natriuretic peptide(NT-proBNP). Methods 90 patients of chronic heart failure who received therapy from January 2013 to January 2016 in the first people's Hospital of Xiangshan, Zhejiang. According to random number table, those patients were divided into the observation group and the control group with 45 cases in each group, on the basis of routine treatment, the control group was treated with benazepril, while the observation group was treated with atorvastatin on the basis of control group. After 2 months, the treatment effect was compared. Results After treatment, the left ventricular end diastolic diameter (LVIDd), left ventricular end systolic diameter (LVIDs) in the observation group were lower than the control group, left ventricular ejection fraction (LVEF) was higher than the control group, the difference was statistically significant (P<0.05), the level of NT-proBNP in the observation group was lower than the control group, the difference was statistically significant (P<0.05), 6 minute walking distance was better than the control group, the difference was statistically significant (P<0.05), the total effective rate in the observation group 91.11%(11/45) was higher than the control group 71.11%(32/45), the difference was statistically significant (P<0.05), during the follow-up of 6 months, the recurrence rate of heart failure in observation group 2.22%(1/45) was lower than the control group 20.00%(9/45), the difference was statistically significant (P<0.05). Conclusion Benazepril combined with atorvastatin is well for chronic heart failure, which can effectively reduce the level of plasma NT-proBNP and prognosis.

chronic heart failurebenazeprilatorvastatinN-terminal pro brain natriuretic peptide

黄健雄、刘晓凯、郑伟峰

展开 >

浙江省象山第一人民医院 心内科,浙江 象山 315700

慢性心力衰竭 贝那普利 阿托伐他汀 氨基末端脑钠肽前体

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(1)
  • 16
  • 11